Stock Ticker

  • Loading stock data...

Merck & Co Inc. (NYSE:MRK) Bolstering Its Oncology Pipeline With Acquisition Of VelosBio

Merck & Co Inc. (NYSE:MRK) has entered a definitive agreement for the acquisition of all outstanding shares of Pappas Capital’s portfolio firm VelosBio via a subsidiary to consider $2.75 billion. However, the closing of the deal is subject to approval under the Hart-Scott-Rodino improvement and customary adjustments. VelosBio developing oncology therapies targeting ROR1 VelosBio is […]

Merck & Co’s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron

Over the years, Merck & Co’s (NYSE:MRK) blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this dominance is about to change. Recently at a cancer research conference, several companies challenged the treatment with their won cancer drugs. Merck’s blockbuster cancer treatment could face competition from new […]

Merck (NYSE:MRK) Makes Investment In Seattle Genetics Inc. (NASDAQ:SGEN) For Development Of Ladiratuzumab Vedotin

Merck (NYSE:MRK) has entered a development agreement for Seattle Genetics Inc. (NASDAQ:SGEN) ladiratuzimab vedotin antibody-drug conjugate (ADC). Merck joins Gilead in investing in ADC-developer with a stake in Seattle Genetics The agreement came hours after Gilead Sciences Inc. (NYSE:GILD) announced the acquisition of Immunomedics for $21 billion. The centerpiece of Gilead’s deal is Immunomedic’s anti-Trop-2 […]

Merck & Co., Inc. (NYSE:MRK) Achieves Limited Success Of Steglatro In Reducing The Risk Of Patients With Total Hospitalizations

Merck & Co., Inc.  (NYSE:MRK) reported only limited success in lowering patients’ total hospitalizations with heart failures. According to recent clinical data, Merck’s Steglatro could overall reduce cardiovascular death or total hospitalization risks by just 17% or lower the risk of the patient by 30%. In a statement, Merck said the first hospitalizations rate remains […]

Merck & Co., Inc. (NYSE:MRK) Gets FDA Nod For ZERBAXA

Merck & Co., Inc. (NYSE:MRK) reported that the U.S. Food and Drug Administration has approved expanded use of its antibiotic to cure hospital-acquired pneumonia in people 18 years and older. This nod comes on the back of the treatment’s late-stage study data, which indicated that Zerbaxa was effective as an antibacterial drug. Zerbaxa was included […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Closes A Licensing Deal With Merck & Co., Inc (NYSE:MRK)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has today moved forward to make an announcement regarding its signing up into some definitive agreement where it was expected to grant Merck & Co., Inc (NYSE:MRK), which is commonly referred to as MSD Animal Health beyond borders of the United States and Canada as well with the full rights to […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Signs a Licensing Deal with Merck & Co., Inc. (NYSE:MRK) Animal Health

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) completes a Definitive Agreement giving Merck & Co., Inc. (NYSE:MRK) Animal Health the rights to build up and distribute Aurinia’s patented nano-micellar cyclosporin ophthalmic solution (VOS) for treating dry eye disorders in dogs. In this agreement, the Aurinia will obtain an upfront payment and they could receive more recompense which will […]

Allergan PLC (NYSE:AGN) To Acquire Rights To Migraine Drugs From Merck & Co., Inc. (NYSE:MRK)

Earlier this week, Allergan PLC (NYSE:AGN) revealed plans to acquire exclusive rights to new migraine drugs from Merck & Co., Inc. (NYSE:MRK). The company announced that the two had closed a $250 million deal for the drugs, and the payment will be on an upfront basis. Merck might also benefit from royalty and milestone payments […]

Merck & Co., Inc.’s (NYSE:MRK) New Cancer Immunotherapy Sales Beat Estimates

Merck & Co., Inc.’s (NYSE:MRK) new cancer therapy Keytruda posted sales of $83 million during 1Q. The sale was better than expected, however, the total revenue and drug sales have reduced from a year ago. Keytruda was approved last September and is Merck’s checkpoint inhibitor for advanced melanoma. The sales in 1Q rose 40% from […]

Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) Prepare for Battle over Next generation Hepatitis C drug

Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) both released new data on their next generation hepatitis C combo. The competition for market share is at an all-time high. Gilead Sciences, Inc. (NASDAQ:GILD) was the first one to release mid-stage data for its triple hepatitis C drug. The drug was combined with the […]

Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) Pair Up for new Cancer Therapy

Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) are collaborating to test their respective cancer therapies in tandem. The collaboration will combine new-fangled therapies that will use the immune system to combat tumours. Under the deal, the duo will jointly fund a Phase I study that combines Juno’s CAR-T therapy and antibodies developed by […]

Keytruda By Merck & Co., Inc. (NYSE:MRK) Is More Effective Than Yervoy of Bristol-Myers Squibb Co (NYSE:BMY),

Merck & Co., Inc. (NYSE:MRK) will file for U.S regulatory approval for the purpose of making their drug Keytruda, marketable. The drug provides treatment for patients with lung cancer. Statistically speaking, people with lung cancer are more than those with melanoma. Moreover, Yervoy, a drug by the Bristol-Myers Squibb Co (NYSE:BMY), which treats melanoma has […]

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Gains $550,000 As EMA Approves Merck & Co., Inc. (NYSE:MRK)’S NOXAFIL®

Boston, MA 09/29/2014 (wallstreetpr) – Ligand Pharmaceuticals Inc. (NASDAQ:LGND) declared that it will receive as much as $550,000 as milestone payment from Merck & Co., Inc. (NYSE:MRK), after the later gained approval for one of its drugs from the European Medicines Agency (EMA). Merck, which is called MSD in countries other than the U.S. and […]

Market Recap: MGM Resorts (MGM), Northstar Realty Finance (NRF) Merck & Co. (MRK)

Boston, MA 09/24/2014 (wallstreetpr) – MGM Resorts International (NYSE:MGM) managed to edge up above 1% on Tuesday even as analysts at Wells Fargo (WFC) eventually moved to downgrade Macau stocks. The firm downgraded Macau because of the almost ever-increasing negative news concerning casino business in the Chinese gambling capital. MGM Resorts and its peers in […]